IMR Press / CEOG / Volume 50 / Issue 5 / DOI: 10.31083/j.ceog5005097
Open Access Review
Study of the Notch-Aromatic Hydrocarbon Receptor-Interleukin-22 Signaling Pathway and the Pathogenesis of Immune Thrombocytopenia
Show Less
1 The Second Clinical College, Lanzhou University, 730030 Lanzhou, Gansu, China
2 Department of Obstetrics, The Second Hospital of Lanzhou University, 730030 Lanzhou, Gansu, China
*Correspondence: (Rong-xia He)
Clin. Exp. Obstet. Gynecol. 2023, 50(5), 97;
Submitted: 11 January 2023 | Revised: 1 April 2023 | Accepted: 14 April 2023 | Published: 12 May 2023
(This article belongs to the Special Issue Pregnancy-associated Immune and Autoimmune Diseases)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Objectives: Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disease characterized by thrombocytopenia. This review will examine the Notch-aromatic hydrocarbon receptor (AhR)-interleukin-22 (IL-22) signaling pathway regulatory mechanisms in ITP to generate ideas for the pathogenesis and etiological investigation of the disease. Mechanism: Studies had shown that an abnormal imbalance of immune cells and immune factors is associated with ITP pathogenesis. The Notch-AhR-IL-22 signaling pathway disrupts the immune microenvironment in vivo, which contributes to the pathogenesis of ITP. Findings in Brief: Several studies have suggested that the pathogenesis of ITP may be mediated by multiple pathways, such as Notch signaling that induces AhR to increase direct secretion of IL-22 from CD4+T cells or the Notch-AhR pathway that induces differentiation of CD4+T cells into Th22 cells to enhance IL-22 expression. However, the precise pathogenic mechanisms are still unknown. Conclusions: ITP pathogenesis is complex, the Notch-AhR-IL-22 signaling pathway may be involved in the pathogenesis of ITP, and further research into the relationship between ITP and this signaling pathway is needed.

immune thrombocytopenia
CY2019-MS11/The Second Hospital of Lanzhou University’s “Science and Technology Innovation” program
Fig. 1.
Back to top